Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases

Simple item page
dc.contributor.authorArturo J Martí-Carvajal
dc.contributor.authorGeorgia Salanti
dc.contributor.authorPedro I. Marti-Carvajal
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:17:57Z
dc.date.available2026-03-22T21:17:57Z
dc.date.issued2007
dc.descriptionCitaciones: 13
dc.description.abstractWe found no evidence that human recombinant activated factor VII reduces the risk of death in patients with liver disease and upper gastrointestinal bleeding. However, we made our conclusion on a single randomised clinical trial. More randomised clinical trials having low risk of bias are necessary in order to determine the role of human recombinant factor VIIa in clinical practice.
dc.identifier.doi10.1002/14651858.cd004887.pub2
dc.identifier.urihttps://doi.org/10.1002/14651858.cd004887.pub2
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/87110
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofCochrane Database of Systematic Reviews
dc.sourceIberoamerican Cochrane Centre
dc.subjectMedicine
dc.subjectCochrane Library
dc.subjectPlacebo
dc.subjectMeta-analysis
dc.subjectRelative risk
dc.subjectClinical trial
dc.subjectInternal medicine
dc.subjectGastrointestinal bleeding
dc.subjectRandomized controlled trial
dc.subjectMEDLINE
dc.titleHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases
dc.typereference-entry

Files

Collections

Otros